Nuveen LLC Acquires Shares of 56,671 Enanta Pharmaceuticals, Inc. $ENTA

Key Points

• Nuveen LLC has made a new investment in Enanta Pharmaceuticals, acquiring 56,671 shares worth approximately $313,000, indicating growing interest in the biotech sector.
• Enanta Pharmaceuticals reported a quarterly earnings per share (EPS) of ($0.85), which beat the consensus estimate of ($1.25) and generated revenue of $18.31 million.
• Analysts have generally rated the stock positively, with a consensus rating of "Buy" and a price target averaging around $22.25, reflecting optimism about the company's future performance.

Nuveen LLC purchased a new position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 56,671 shares of the biotechnology company's stock, valued at approximately $313,000. Nuveen LLC owned approximately 0.27% of Enanta Pharmaceuticals at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of ENTA. Wells Fargo & Company MN increased its holdings in shares of Enanta Pharmaceuticals by 69.6% in the fourth quarter. Wells Fargo & Company MN now owns 15,881 shares of the biotechnology company's stock worth $91,000 after acquiring an additional 6,518 shares in the last quarter. Barclays PLC boosted its position in shares of Enanta Pharmaceuticals by 65.9% during the fourth quarter. Barclays PLC now owns 45,508 shares of the biotechnology company's stock worth $262,000 after buying an additional 18,070 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Enanta Pharmaceuticals by 52.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 297,106 shares of the biotechnology company's stock worth $1,708,000 after buying an additional 102,646 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of Enanta Pharmaceuticals by 46.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company's stock worth $41,000 after buying an additional 2,274 shares during the period. Finally, Jane Street Group LLC boosted its position in shares of Enanta Pharmaceuticals by 34.1% during the fourth quarter. Jane Street Group LLC now owns 31,072 shares of the biotechnology company's stock worth $179,000 after buying an additional 7,896 shares during the period. 94.99% of the stock is currently owned by institutional investors.

Enanta Pharmaceuticals Stock Performance

NASDAQ ENTA traded up $0.33 during trading hours on Thursday, hitting $8.66. 208,050 shares of the company traded hands, compared to its average volume of 148,179. The business's 50-day moving average is $7.85 and its 200-day moving average is $6.80. Enanta Pharmaceuticals, Inc. has a twelve month low of $4.09 and a twelve month high of $13.37. The stock has a market capitalization of $185.15 million, a price-to-earnings ratio of -2.00 and a beta of 0.84.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($1.25) by $0.40. Enanta Pharmaceuticals had a negative return on equity of 89.02% and a negative net margin of 141.98%.The firm had revenue of $18.31 million during the quarter, compared to analysts' expectations of $16.21 million. Analysts predict that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current year.

Analyst Ratings Changes

ENTA has been the subject of several recent research reports. HC Wainwright initiated coverage on Enanta Pharmaceuticals in a research report on Monday, July 28th. They set a "buy" rating and a $20.00 price objective for the company. Wall Street Zen raised Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Sunday, June 22nd. Westpark Capital initiated coverage on Enanta Pharmaceuticals in a research report on Tuesday, September 2nd. They set a "buy" rating and a $24.00 price objective for the company. Finally, JMP Securities upped their price objective on Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a "market outperform" rating in a research report on Tuesday, August 12th. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $22.25.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.